​

Kymera Therapeutics Stock (NASDAQ:KYMR)

ForecastRevenueOwnershipFinancialsChartTranscripts
Kymera Therapeutics by TradingView

Previous Close

$45.85

52W Range

$19.45 - $53.27

50D Avg

$41.89

200D Avg

$39.24

Market Cap

$3.21B

Avg Vol (3M)

$864.35K

Beta

2.19

Div Yield

-

KYMR Company Profile

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

208

IPO Date

Aug 21, 2020

Website

KYMR Performance

KYMR Financial Summary

Dec 24Dec 23Dec 22
Revenue$47.07M$78.59M$46.83M
Operating Income$-261.63M$-165.53M$-161.26M
Net Income$-223.86M$-146.96M$-151.83M
EBITDA$-261.63M$-143.20M$-151.66M
Basic EPS$-2.98$-2.52$-2.82
Diluted EPS$-2.98$-2.52$-2.82

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 09, 25 | 10:00 AM
Q4 24Feb 27, 25 | 8:30 AM
Q3 24Nov 03, 24 | 7:30 AM

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
RVMDRevolution Medicines, Inc.
CCCCC4 Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
ITOSiTeos Therapeutics, Inc.
ARVNArvinas, Inc.